- Home
- » Tags
- » Alkermes (company)
Top View
- United States District Court for the District of Columbia
- ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements for the Nine Months Ended December 31, 2013 ALKERMES PLC Table of Contents
- Astellas Research Institute of America LLC: Employee (Self) Adinoff, Bryon: Journal Editor: Board Member (Self)
- Signatory Companies
- Neoadjuvant Therapy for Melanoma: a U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop a C Kristen L
- 2017 Regional Chain Conference Strategic Partners Profiles FLOOR PLAN
- 2021 Jp Morgan Healthcare Conference: Preview
- Moderna 2021 Proxy Statement
- Jazz Pharmaceuticals Plc Proxy Statement 2017 Annual Report
- WDD License # Expiration Effective License Holder Name
- Alkermes Announces Approval in Germany for Risperdal Consta; First Atypical Antipsychotic to Be Available As Long-Acting Injection
- United States District Court for the District of Columbia
- UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
- 1 Alkermes Public Limited Company Directors' Report
- Alkermes Announces Approval in United Kingdom for Risperdal Consta
- Smaller Companies Win in Most Valuable Race
- Member Since (Alphabetical Order) 1976 3M Medical Solutions Division 2019 Electrocore, Inc
- Alkermes Appoints Craig Hopkinson, M.D., As Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs
- ASCP 2018 ANNUAL MEETING: Treatment of Psychiatric Illness Across the Lifespan
- CNS SPECTRUMS CME Review Article Long-Acting Injectable Antipsychotics: What, When, and How
- Jazz Pharmaceuticals
- 1976 3M Medical Solutions Division 2019 Electrocore, Inc
- Disclosure Statements
- UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
- Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
- Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma Robert H.I
- Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a Pharmaceutical Or Biotechnology
- Value Creation at Alkermes: Focused on Innovation, Growth and Profitability
- CSG Leadership Circle Alexion Pharmaceuticals Alkermes Esri Everytown for Gun Safety HCA Healthcare Juul Labs Intuit Novo Nordis
- Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
- Breaking the Barrier: Getting Beyond 50% Long-Term Survival for Patients with Advanced Melanoma
- Disclosure Index - Sessions
- Innovative Mid-Cap Biotechnology Benchmark Report Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
- P Number Manufacturer Name P1001 Forest Laboratories, Inc. P1002
- Jazz Pharmaceuticals Plc Proxy Statement 2019 Annual Report TIM
- Attendee List
- TXM (October 2021) Classes to Be Reviewed.Xlsx